SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-008023 to CEL SCI CORP (CVM)

CEL SCI CORP
Date: July 30, 2025 · CIK: 0000725363 · Accession: 0000000000-25-008023

AI Filing Summary & Sentiment

Date
July 30, 2025
Author
Not clearly detected
Form
UPLOAD
Company
CEL SCI CORP

Letter

July 30, 2025 Geert Kersten Chief Executive Officer Cel-Sci Corporation 8229 Boone Blvd. #802 Vienna, VA 22182 Re:Cel-Sci Corporation Draft Registration Statement on Form S-1 Submitted July 25, 2025 CIK No. 0000725363 Dear Geert Kersten: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:William Hart, Esq.

Show Raw Text
July 30, 2025
Geert Kersten
Chief Executive Officer
Cel-Sci Corporation
8229 Boone Blvd. #802
Vienna, VA 22182
Re:Cel-Sci Corporation
Draft Registration Statement on Form S-1
Submitted July 25, 2025
CIK No. 0000725363
Dear Geert Kersten:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement at least two business
days prior to the requested effective date and time. Please refer to Rules 460 and 461
regarding requests for acceleration. We remind you that the company and its management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or absence of action by the staff.
            Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:William Hart, Esq.